We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First Direct Measurement of Dementia-Linked Proteins to Enable Early Alzheimer’s Detection

By LabMedica International staff writers
Posted on 10 Nov 2025

The disease process in Alzheimer’s begins long before memory loss or cognitive decline becomes apparent. More...

During this silent phase, misfolded proteins gradually form amyloid fibrils, which accumulate in the brain and cause irreversible damage. Current diagnostic techniques can rarely identify these early changes, meaning treatments often begin too late to be effective. Now, a breakthrough method could help detect the earliest stages of Alzheimer’s disease years before symptoms appear.

For the first time, researchers at Utrecht University (Utrecht, Netherlands) have made the growth of harmful protein clumps involved in dementias such as Alzheimer’s, Parkinson’s, and Huntington’s directly measurable — even in blood samples. The team, in collaboration with colleagues from international institutes, has developed FibrilPaint — a new class of molecules that “paint” the earliest fibril formations. FibrilPaint binds specifically to the thread-like amyloid protein aggregates characteristic of dementia and emits fluorescent light when exposed to specialized imaging equipment.

This fluorescence not only confirms the presence of the fibrils but also reveals their length and growth stage, offering a measurable indicator of disease progression. Importantly, FibrilPaint allows scientists to analyze blood and cerebrospinal fluid directly, eliminating the complex, time-consuming pretreatment steps required by existing methods.

The researchers believe FibrilPaint could revolutionize both early diagnosis and drug development for neurodegenerative diseases. By tracking disease progression in unprecedented detail, the technique, published in the journal PNAS, will allow clinicians to evaluate treatment effectiveness in real time.

“With our technique, we will soon be able to monitor the progression of the disease much more precisely and determine whether a treatment is effective,” said Françoise Dekker, a chemist at Utrecht University. “Our technique will eventually allow us to follow the course of the disease much more accurately and see whether a treatment really works.”

Related Links:
Utrecht University


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Noul’s AI-based cervical cancer diagnostic solution, miLab CER (Photo courtesy of Noul)

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.